Home Equity Borrowing Costs Remain Low but Fed Rate Path Could Shift Borrowing Calculus
SpaceX Scrubs Starship V3 Test Flight Rescheduled for Friday Launch
Wall Streets Top Pick for Further Research Amid Two Stocks to Approach with Caution
JP Morgan Lowers Price Target on Banco Bilbao Vizcaya Argentaria BBVA but Retains Overweight Rating
Indias Trucking Sector Faces Operational Crisis Amid Diesel Price Hikes and Fuel Shortages
Aluminum Prices Surge Amid Geopolitical Tensions How Major US Companies Navigate Rising Costs
DTIL Q1 2026 Earnings EPS Misses Estimates as PreCommercial Biotech Advances Pipeline
CPSS Q4 2025 Earnings Mixed Results as EPS Falls Short of Estimates
IVVD Q1 2026 Earnings WiderthanExpected Loss Amid Continued Pipeline Development
Ituran ITRN Q4 2025 Earnings EPS Slightly Beats Estimates Amid Positive Stock Movement
Transcontinental Realty Investors Inc TCI Q1 2025 Earnings Positive Earnings Amid Quiet Reporting
Saga Communications SGA Q1 2026 Earnings Broadcast Loss Widens Amid Ad Market Pressure
FIS Edges Lower Amid Consolidation as Stock Hovers Near Support Levels
Trinity Capital Notes TRINI Edge Higher as Yield Stability Attracts Steady Demand
Nuveen Municipal Credit Income Fund NZF Rises Modestly as Steady Demand Supports FixedIncome Assets
Plum Acquisition Corp IV Unit PLMKU Holds Steady at 1088 With No Price Change
Eledon Pharmaceuticals ELDN Holds Steady at 389 as Trading Range Consolidates
Vodafone Q4 2025 Earnings EPS Beat of 4078 Surprises but Stock Slips on Cautious Outlook
SBFM Q1 2026 Earnings PreRevenue Biotech Reports Net Loss of 025 Per Share Stock Falls 25
Hecla Mining Q1 2026 Earnings EPS Falls Short of Expectations Amid Cost Pressures
SAM Q1 2026 Earnings EPS Misses Estimates Stock Still Gains Ground
Joby Aviation Q1 2026 Earnings EPS Surprise Beats Estimates Amid Certification Progress
Atossa Therapeutics Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Advances
A Funds 28 Million Exit From a SaaS Stock After a 15 Decline What It Signals
MPLT Q1 2026 Earnings WiderThanExpected Loss and Stock Decline Amid ClinicalStage Pipeline Development
Bicara Therapeutics BCAX Edges Higher as Stock Tests Key Resistance Zone